GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADMA Biologics Inc (NAS:ADMA) » Definitions » Cyclically Adjusted PB Ratio

ADMA Biologics (ADMA Biologics) Cyclically Adjusted PB Ratio : 13.82 (As of Jun. 05, 2024)


View and export this data going back to 2013. Start your Free Trial

What is ADMA Biologics Cyclically Adjusted PB Ratio?

As of today (2024-06-05), ADMA Biologics's current share price is $10.09. ADMA Biologics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $0.73. ADMA Biologics's Cyclically Adjusted PB Ratio for today is 13.82.

The historical rank and industry rank for ADMA Biologics's Cyclically Adjusted PB Ratio or its related term are showing as below:

ADMA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.04   Med: 3.1   Max: 13.52
Current: 13.52

During the past years, ADMA Biologics's highest Cyclically Adjusted PB Ratio was 13.52. The lowest was 1.04. And the median was 3.10.

ADMA's Cyclically Adjusted PB Ratio is ranked worse than
94.05% of 656 companies
in the Biotechnology industry
Industry Median: 1.745 vs ADMA: 13.52

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ADMA Biologics's adjusted book value per share data for the three months ended in Mar. 2024 was $0.663. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.73 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


ADMA Biologics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for ADMA Biologics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADMA Biologics Cyclically Adjusted PB Ratio Chart

ADMA Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.28 2.01 1.29 4.93 6.01

ADMA Biologics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.29 4.67 4.39 6.01 9.09

Competitive Comparison of ADMA Biologics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, ADMA Biologics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ADMA Biologics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADMA Biologics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ADMA Biologics's Cyclically Adjusted PB Ratio falls into.



ADMA Biologics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

ADMA Biologics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=10.09/0.73
=13.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADMA Biologics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, ADMA Biologics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.663/131.7762*131.7762
=0.663

Current CPI (Mar. 2024) = 131.7762.

ADMA Biologics Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.324 100.560 1.735
201409 0.995 100.428 1.306
201412 0.647 99.070 0.861
201503 1.254 99.621 1.659
201506 0.889 100.684 1.164
201509 0.459 100.392 0.602
201512 0.077 99.792 0.102
201603 -0.314 100.470 -0.412
201606 0.304 101.688 0.394
201609 -0.012 101.861 -0.016
201612 -0.346 101.863 -0.448
201703 -0.835 102.862 -1.070
201706 1.073 103.349 1.368
201709 0.504 104.136 0.638
201712 0.890 104.011 1.128
201803 0.508 105.290 0.636
201806 1.117 106.317 1.384
201809 0.803 106.507 0.994
201812 0.427 105.998 0.531
201903 0.217 107.251 0.267
201906 0.791 108.070 0.965
201909 0.609 108.329 0.741
201912 0.442 108.420 0.537
202003 1.116 108.902 1.350
202006 0.890 108.767 1.078
202009 0.796 109.815 0.955
202012 0.841 109.897 1.008
202103 0.914 111.754 1.078
202106 0.846 114.631 0.973
202109 0.743 115.734 0.846
202112 0.721 117.630 0.808
202203 0.646 121.301 0.702
202206 0.583 125.017 0.615
202209 0.510 125.227 0.537
202212 0.685 125.222 0.721
202303 0.655 127.348 0.678
202306 0.654 128.729 0.669
202309 0.670 129.860 0.680
202312 0.598 129.419 0.609
202403 0.663 131.776 0.663

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ADMA Biologics  (NAS:ADMA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


ADMA Biologics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of ADMA Biologics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ADMA Biologics (ADMA Biologics) Business Description

Traded in Other Exchanges
N/A
Address
465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Executives
Alison Cecily Finger director C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Jerrold B Grossman director 65 COMMERCE WAY, HACKENSACK NJ 07601
Young Kwon director C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Adam S Grossman director, officer: President and CEO 65 COMMERCE WAY, HACKENSACK NJ 07601
Brian Lenz officer: EVP, CFO 65 COMMERCE WAY, HACKENSACK NJ 07601
Lawrence P. Guiheen director 65 COMMERCE WAY, HACKENSACK NJ 07601
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
James Mond officer: CSO/CMO 65 COMMERCE WAY, HACKENSACK NJ 07601
Biotest Divestiture Trust 10 percent owner C/O ERIC ROSENBACH, TRUSTEE, 402 NORFOLK STREET, CAMBRIDGE MA 02139
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Biotest Pharmaceuticals Corp director, 10 percent owner 5800 PARK OF COMMERCE BLVD., NW, BOCA RATON FL 33487